FOXO4-DRI
FOXO4-DRI (D-retro-inverso FOXO4 peptide)
Get FOXO4-DRI
Sourced from Ascension Peptides. Verified ≥99+% purity, third-party tested. COA included.
Off with code
PEPTIDEDECK
Table of Contents
What is FOXO4-DRI?
FOXO4-DRI is a designed peptide that emerged from senescence research, an area of aging biology focused on cells that have permanently stopped dividing but persist in tissues instead of being cleared. These senescent cells accumulate with age and secrete inflammatory signals that can damage surrounding tissue, contributing to aging and age-related disease. FOXO4-DRI was created as a molecular tool to selectively eliminate such cells.
FOXO4-DRI is based on a segment of the FOXO4 protein, specifically the region through which FOXO4 engages the tumor suppressor p53. The peptide is engineered as a D-retro-inverso construct, a well-established strategy in peptide design. In this approach, the amino acids are the mirror-image D-form rather than the usual L-form, and their order is reversed. The combined effect is a molecule whose overall shape and binding surface closely resemble the original but which is highly resistant to the enzymes that would rapidly degrade a normal peptide.
FOXO4-DRI belongs to the broader class of senolytics, agents intended to clear senescent cells. Its distinguishing feature is the specific mechanism it targets: rather than acting through a general stress or survival pathway, it directly disrupts the FOXO4-p53 partnership that senescent cells depend on. This precision has made FOXO4-DRI an influential experimental probe for testing the hypothesis that removing senescent cells can improve tissue function in aging.
Research Benefits
Studied as a selective senolytic research peptide
Designed to disrupt FOXO4-p53 signaling in senescent cells
D-retro-inverso structure improves protease resistance
Used in cellular aging and senescence pathway research
How FOXO4-DRI Works
FOXO4-DRI works by disrupting a protein-protein interaction that senescent cells use to avoid death. Understanding its mechanism requires understanding the unusual relationship between FOXO4 and p53 inside these cells, and how breaking that relationship tips a senescent cell toward self-destruction.
The FOXO4-p53 Survival Axis
FOXO4-DRI targets the way senescent cells manage p53, a protein best known as a guardian that can trigger apoptosis in response to cellular damage. In senescent cells, the protein FOXO4 binds p53 and sequesters it in the nucleus, preventing it from carrying out its pro-death function. This arrangement is part of how senescent cells remain in a stable, non-dividing but stubbornly alive state despite carrying substantial damage.
Interaction Disruption
Competes with FOXO4 for binding to p53, breaking the survival partnership.
p53 Release
Frees p53 from nuclear sequestration so it can act on the cell's death machinery.
Selective Apoptosis
Drives senescent cells toward programmed death while largely sparing healthy cells.
Stability by Design
The D-retro-inverso structure resists degradation, letting it reach its target.
Releasing p53 to Trigger Cell Death
FOXO4-DRI competes with native FOXO4 for binding to p53. When the peptide displaces FOXO4, p53 is freed from its nuclear tether and can relocate to the mitochondria, where it participates in initiating apoptosis. In a senescent cell that has been depending on the FOXO4-p53 restraint to stay alive, this release of p53 removes the brake and allows the cell's own death program to proceed.
Why Selectivity Matters
FOXO4-DRI's appeal as a research senolytic rests on this differential dependence. An ideal senolytic clears the harmful senescent cells while leaving normal, functioning cells intact, avoiding broad toxicity. By exploiting a survival mechanism that senescent cells rely on more heavily than healthy cells, FOXO4-DRI aims for that selectivity, and it has been used experimentally to test whether targeted removal of senescent cells can restore aspects of tissue function.
Research Applications
Cellular senescence
Active research area with published studies
Aging biology
Active research area with published studies
SASP signaling
Active research area with published studies
Senolytic screening
Active research area with published studies
Research Findings
FOXO4-DRI has been studied primarily in laboratory and preclinical models of aging and senescence, where it serves as a proof-of-concept tool for the senolytic strategy of clearing senescent cells to improve tissue health.
Cellular Senescence Research
FOXO4-DRI is used in senescence research to test whether disrupting the FOXO4-p53 interaction can selectively eliminate senescent cells in culture. Studies in cellular models have examined how the peptide induces death in senescent cells while having limited effect on healthy dividing cells, supporting its intended selectivity and validating the FOXO4-p53 axis as a senolytic target.
🔑 Key Research Observations
- FOXO4-DRI targets the FOXO4-p53 interaction that senescent cells use to avoid apoptosis
- In cellular models it preferentially eliminates senescent cells over healthy cells
- It is used to test the senolytic hypothesis that clearing senescent cells improves tissue function
- The D-retro-inverso design provides the stability needed for experimental use
- Findings are preclinical, and human safety and efficacy are not established
Preclinical Aging Models
FOXO4-DRI has been investigated in animal models relevant to aging, where researchers assess whether clearing senescent cells affects measures of tissue function and overall condition. This line of work is part of the broader senolytics field, which explores whether the targeted removal of senescent cells can counter aspects of aging and age-associated decline. As with all preclinical research, results in these models are a starting point for hypotheses rather than evidence of human benefit.
| Research Context | Question Explored | Evidence Stage |
|---|---|---|
| Cell culture | Selective killing of senescent cells | Preclinical |
| Aging models | Effect of senescent cell clearance | Preclinical |
| Senescence signaling | Role of FOXO4-p53 axis | Mechanistic research |
Place Within Senolytics Research
FOXO4-DRI is notable for demonstrating a precise, interaction-specific approach to senolysis, distinct from small-molecule senolytics that act on other survival pathways. Its use has helped shape thinking about how senescent cells maintain their resistance to death and how that resistance might be exploited to clear them selectively. The peptide remains an investigational research tool, and its findings contribute to a rapidly developing but still early field.
Dosage & Administration
FOXO4-DRI dosing information does not exist in the form of established human protocols, and the notes below describe how the peptide is handled in research settings only. FOXO4-DRI is strictly a research compound, and any handling should occur within a properly equipped and supervised laboratory setting, not in humans.
Formulation and Handling
FOXO4-DRI is typically supplied as a lyophilized (freeze-dried) powder that must be reconstituted before use in experiments. In laboratory work it is dissolved in an appropriate solvent or buffer according to the study design, and its D-retro-inverso construction gives it enough stability to remain intact through experimental handling that would degrade an ordinary peptide.
Laboratory Reconstitution Practices
Prepare Materials
Gather the powder vial, an appropriate sterile diluent or buffer, and clean handling supplies.
Add Diluent Gently
Introduce the diluent slowly and allow the peptide to dissolve without vigorous agitation.
Aliquot for Use
Divide the solution into working aliquots to minimize repeated freeze-thaw cycles.
Store Cold
Keep the powder and reconstituted solution cold and protected from degradation per protocol.
Research-Only Context
| Aspect | Research Practice | Reason |
|---|---|---|
| Form | Lyophilized powder | Stability for storage and shipping |
| Preparation | Reconstituted per protocol | Match experimental requirements |
| Use | Laboratory models only | No approved human application |
Practical Insight
Because FOXO4-DRI is a research reagent rather than a medicine, its handling is governed by laboratory protocols and its stability advantages come from the D-retro-inverso design, which is the main reason this construction was chosen over a conventional peptide.
Safety & Side Effects
FOXO4-DRI safety in humans is not established, because the peptide has been studied in laboratory and preclinical models rather than in the clinical trials required to characterize human safety. Its considerations are therefore framed around its mechanism and its research-only status.
Mechanism-Based Considerations
FOXO4-DRI acts by releasing p53 to trigger apoptosis in senescent cells, and the considerations around it follow from that powerful mechanism.
Research-Only Use
Intended for laboratory study, without established human safety data.
Selectivity Depends on Context
Preferential effect on senescent cells is central, and off-target effects are a research concern.
Potent Pathway
Modulating p53-driven apoptosis is a strong intervention that requires careful study.
Purity Matters
As with any research peptide, quality and correct handling affect experimental outcomes.
Key Points on Safety
FOXO4-DRI safety discussion centers on the following points:
- No human data: There are no adequate human studies defining its safety, tolerability, or side effect profile
- Apoptosis induction: Because it drives programmed cell death, any effect on non-target cells is a central research question rather than a settled issue
- p53 biology: p53 is a critically important protein, and interventions affecting its regulation must be studied carefully for unintended consequences
- Unregulated products: Material sold outside research channels lacks quality assurance, which compounds the risk of using an already investigational compound
Research Context
FOXO4-DRI belongs to an active but early field, and its safety evaluation remains a matter for controlled preclinical and, eventually, clinical study rather than informal use. Responsible handling means treating it as the laboratory reagent it is, with no assumption that preclinical selectivity translates directly into human safety.